Skip to content

Ketamine derived Nasal Spray for Depression - A review

International Journal of Research in Pharmaceutical Sciences September 11, 2020 DOI: 10.26452/ijrps.v11ispl3.2926 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Systematic review Peer reviewed
Intervention Ketamine
Topics Depression Esketamine Ketamine
Key findings Argues that intranasal ketamine is more efficient as an antidepressant than many other drugs and should be brought to the medicinal market as a nasal spray, while calling for further animal and clinical trials to establish its short- and long-term effects.

Abstract

Depression is a mood disorder; it affects a person's life in all terms of his daily life. Normally depressions are mood swings exposed as feelings which may be sadness, loss, anger, even laughter. Depression now stands first than any other psychological illness is causing increased mortality in the population. Major depressive disorders [MDD] is one of the major causes of mortality in the population. So, antidepressants are used which could relieve the subject from the effects of Depression. Ketamine is a recently developed drug to fortify the qualities of an antidepressant. This article is the review of previous research articles that were done on ketamine and its effects on Depression as a nasal spray. A systematic review is done on various aspects of ketamine on Depression. Efficiency, effects and a few other factors are analyzed in a comparative manner. Depression should be considered as a global issue. Ketamine being efficient as an antidepressant than many other drugs should be brought into the medicinal market as a nasal spray. Intranasal ketamine was directed into the body passing biphasic stage 1. It avoids most of the inhibitory pathways. Their effects are stronger and more effective in the form of a nasal spray. Short term and long-term effects should be analyzed. Further research is the need of the hour many more animal and clinical trials should be done to know about its complete purpose to humanity.

Comparable studies

Other systematic reviews and meta-analyses on ketamine for depression, most cited first.

Study Year Design Participants
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression Participants with major depression in placebo-controlled, double-blind, randomized... 2015 Systematic review and meta-analysis
Side-effects associated with ketamine use in depression: a systematic review. Patients with depression 2018 Systematic review
Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis Adults with unipolar or bipolar major depression 2020 Systematic review and meta-analysis n = 1,877
Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories Patients with major depressive disorder or bipolar depression 2016 Systematic review and meta-analysis n = 588
The use of ketamine as an antidepressant: a systematic review and meta‐analysis People with major depressive disorder or bipolar disorder receiving ketamine infusion 2015 Meta-analysis n = 437

Explore topics

By condition and practice